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Summary 
Purpose: Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as 
second-line treatment of status epilepticus (SE), but comparative studies are not available.  
Methods:  Among 279 adult SE episodes identified prospectively in our tertiary care hospital over 
four years, we retrospectively identified 187 episodes in which PHT, VPA or LEV were given after 
benzodiazepines. Patients with post-anoxic SE were not included. Demographics, clinical SE 
features, failure of second-line treatment to control SE, new handicap and mortality at hospital 
discharge were assessed. Uni- and multivariable statistical analyses were applied to compare the 
three agents. 
Key findings: Each compound was used in about one third of SE episodes. VPA failed to control 
SE in 25.4%, PHT in 41.4% and LEV in 48.3% of episodes in which these were prescribed. A 
deadly etiology was more frequent in the VPA group, while SE episodes tended to be more severe 
in the PHT group. After adjustment for these known SE outcome predictors, LEV failed more often 
than VPA (OR 2.69; 95% CI: 1.19 - 6.08); 16.8% (95% CI: 6.0% - 31.4%) of second-line treatment 
failures could be attributed to LEV. PHT was not statistically different from the other two 
compounds. Second-line treatment did not seem to influence new handicap and mortality, while 
etiology and the SE Severity Score (STESS) were robust independent predictors. 
Significance: Even without significant differences on outcome at discharge, LEV seems less 
efficient than VPA to control SE after benzodiazepines. A prospective comparative trial is needed 
to address this potentially concerning finding.   
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Status epilepticus (SE) represents a severe condition with significant mortality and morbidity 
(Coetaux et al., 2000; Knake et al., 2001; Vignatelli et al., 2003), and its timely treatment is 
indicated to prevent potentially deleterious complications (Lowenstein & Alldredge, 1998). 
Unfortunately, high-level evidence is only available for the first-line medication; in particular, 
lorazepam has been shown to be more effective than phenytoin (PHT) or placebo (Trieman et al., 
1998; Alldredge et al, 2001); therefore, intravenous benzodiazepines are recommended as initial 
approach (Meierkord et al., 2010). However, since first-line therapy fails to control at least 35-45% 
of patients with SE (Trieman et al., 1998), additional treatments are needed, for whom convincing 
evidence is lacking. Historically, PHT (Pilz & Dreyer, 1969; Wallis et al., 1968) has been used 
before valproic acid (VPA) (Sinha et al., 2000; Trinka, 2009) as a second-line agent. The Veteran 
Affairs study (Trieman et al., 1998) together with other smaller series (Misra et al., 2006; Gilad et 
al., 2008) showed that PHT is useful as first-line therapy, but comparative investigations using those 
compounds as second-line treatment after benzodiazepines are very scarce. A small prospective 
randomized study (Agarwal et al., 2007) analyzed PHT and VPA after diazepam failure and showed 
that both drugs were surprisingly highly effective (controlling SE in 88% and 84 % of patients, 
respectively). More recently, levetiracetam (LEV) (Rossetti et al., 2006a; Knake et al., 2008) and, to 
a much more limited extent, lacosamide (Kellinghaus et al., 2011) have also been described for this 
indication, but again without any comparison to other agents.  
To address this relevant lack of information, we used our SE database to investigate the relative role 
of PHT, VPA and LEV in the treatment of SE as second-line agents. We did not consider 
lacosamide, as it was marketed in Switzerland only in September 2009, while all other drugs were 
available before 2006.  
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Methods 
Patients and procedures 
We retrospectively analyzed data from a prospective registry including all patients treated at our 
center (tertiary hospital) over four years for SE, between April 1st 2006 and March 31 2010. Details 
on the registry were recently published in another study (Novy et al., 2010). Briefly, SE was 
defined as the continuous occurrence of seizures for more than five minutes, or repeated epileptic 
seizures without intercurrent baseline recovery. Seizures were diagnosed clinically, but formal EEG 
confirmation was required for non-convulsive episodes. SE episodes were identified and screened 
by our neurological consultants at the emergency unit and intensive care unit, and by the EEG staff. 
Subjects younger than 16 years old and patients with post-anoxic SE were not included. We 
indentified all SE episodes in which a second-line treatment was prescribed.  
Our protocol to treat SE starts with intravenous benzodiazepines (clonazepam 0.015 mg/kg or 
lorazepam 0.1 mg/kg), followed by a choice of PHT 20 mg/kg, VPA 20 mg/kg or LEV 20 mg/kg; 
all are relayed by maintenance dosages (typically, 300-400 mg PHT, 1000-2500 mg VPA, or 1000-
3000 mg LEV daily). The second-line treatment is typically administered within 1-30 minutes 
following benzodiazepines. The vast majority of these drugs are given intravenously. Every case is 
discussed within 48 hours with one of both senior epileptologist of our center to guide SE treatment 
after the application of the initial algorithm. 
Variables 
Age, gender, history of previous seizures, seizures type (partial versus generalized), consciousness 
before treatment institution, treatments, and SE etiology were recorded prospectively. 
Consciousness was categorized as alert/confuse/somnolent versus stuporous/comatose. For each 
patient, a validated SE severity score (STESS) was calculated (Rossetti et al., 2008) and its scores 
categorized in ≥ 3 or < 3 (Table 1). Etiology was considered “deadly” if leading to death if not 
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specifically treated, as previously described (Rossetti et al., 2006b), including: massive ischemic 
and hemorrhagic stroke, primary or secondary cerebral tumor, CNS infection, severe autoimmune 
disease, AIDS with CNS complication, metabolic disturbance sufficient to cause coma, eclampsia, 
and sepsis. We also categorized etiology as acute vs. non-acute (Commission on Epidemiology and 
Prognosis, ILAE, 1993). The primary outcome was the failure of the second-line treatment, defined 
as the need to introduce a further compound to control SE. We considered SE as controlled if no 
change in antiepileptic medication was needed for at least 48 hours after clinical and 
electrographical resolution. We developed a specific multilevel variable to define second-line 
treatment, where each compound represented one level of the variable (VPA being the reference, 
the second level was PHT, and the third was LEV). We also prospectively recorded, at hospital 
discharge, mortality (calculated using patients instead of episodes as denominator), new handicap 
(failure to return to baseline clinical conditions), or return to baseline.  
Statistical analyses 
Comparisons among the three treatment groups were performed using two-tailed Fisher exact, χ2, or 
ANOVA tests, as required. In order to adjust the results for possible confounders, variables with 
p<0.2 were entered in stepwise logistic regressions using the outcome as dependent variable; 
goodness of fit was evaluated using a χ2 test. The population attributable fraction (PAF) of failure of 
the second-line treatment when using the worst acting agent was calculated using the formula 
(Miettinen, 1974; Hanley 2001):  
[Prevalence of patients exposed to the second-line treatment in the failure cases] x [(Odds Ratio-1)/Odds Ratio]  
To perform a multivariate analysis and generate an adjusted estimate of the PAF of failure of the 
second-treatment, we determined the PAF for multiple levels of exposure defined as above. 
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Results 
We indentified 198 SE episodes (representing 71% of 279 episodes in our database), occurring in 
167 patients, during which BZD were followed by a second-line agent. Only 8 episodes (4%) lasted 
less than 30 minutes. While in eleven episodes other oral agents were prescribed after failure of 
BZD (3 received carbamazepine, 3 pregabaline, 2 lamotrigine, 2 gabapentin and 1 phenobarbital), 
analysis was restricted to the 187 episodes in which PHT (70 episodes, 37%), VPA (59 episodes, 
32%), or LEV (58 episodes, 31%) were used as second-line agents.  
An overview of the treatment groups is presented in Table 2; several potentially important 
differences were observed. In the unadjusted analysis, patients treated with VPA had fewer 
unfavorable outcomes than the other two groups (failure of second-line agent, p=0.032; new 
morbidity or death, p=0.011; mortality, p= 0.045). VPA failed to control the SE in 25.4%, PHT in 
41.4% and LEV in 48.3%. In the eleven subjects who received others agents, this corresponded to 
28% (3/11).  
Patients with a deadly etiology (p <0.001) and an acute etiology (p=0.035) were more frequent in 
the LEV and PHT groups than in the VPA group, and subjects treated with VPA and LEV tended to 
have less severe SE episodes than patients of the PHT group (p = 0.007). The constitutive variables 
of the STESS (severe consciousness impairment, convulsive seizure, lack of previous seizures, 
higher age) were more frequently represented in the PHT group, except for age. Of note, treatment 
was started within an hour of symptoms onset in 48.5% of patients in the PHT, 30.5% in the VPA, 
and 29.5% in the LEV group (p= 0,03, χ2; the difference between VPA and LEV being not 
significant). Discrepancies in SE severity and etiology may have played a major role regarding the 
outcomes; therefore, a multivariable approach was applied.  
Logistic regression analyses were performed for the three outcomes, using VPA as the reference 
treatment (table 3). All models showed an acceptable to excellent goodness of fit (second-line 
treatment failure: p=0.89; new morbidity or mortality: p=0.38; mortality: p=0.21). After 
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adjustments for SE severity and etiology, LEV was still related to a higher risk of second-line 
treatment failure as compared to VPA, (OR 2.7, 95% CI 1.2 - 6.1). Treatment failures (PAF) 
attributable to the use of LEV corresponded to 16.8% (95% CI 6.0 – 31.4 %), suggesting that 16.8% 
of second-line medication failures might have been avoided using VPA instead of LEV. PHT did 
not differ significantly from the other two compounds. 
On the other side, the choice of the second-line treatment did not influence mortality and persistent 
morbidity at discharge (Table 3), while a STESS score ≥3 and a deadly etiology for the SE were 
strongly predictive for unfavorable outcome.  
 
Discussion 
As opposed to the few comparative studies investigating the administration of VPA and PHT in SE 
(Mirsa et al., 2006; Gilad et al., 2008; Agarwal et al., 2007), which despite several methodological 
pitfalls suggest that these compounds are broadly comparable, LEV has not been tested against any 
other antiepileptic drug so far. This observational study suggests that the agent administered after 
benzodiazepines in patients with SE may influence the immediate treatment success, but not the 
outcome at hospital discharge: LEV seems to bear a higher risk of immediate treatment failure as 
compared to VPA, with 16.8% of treatment failures attributable to LEV, with PHT being in 
between.   
It exists a paradox in the SE treatment, since practical and financial issues, and the position taken by 
regulatory authorities, render a prospective trial extremely difficult. A physician can chose among 
VPA, PHT, LEV and even other compounds, in an almost complete absence of rational evidence, 
but can not collect information to determine efficacy without getting informed consent from the 
patient, which in an emergency condition is extremely difficult. In order to attenuate the lack of 
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information in this field, we therefore used a sort of “natural experiment”, analyzing the real-world 
use of these compounds in SE and their efficacy,  
In this cohort, PHT was prescribed slightly more often as a second-line drug, probably because of 
the historical experience with this substance (Pilz & Dreyer, 1969; Wallis et al. 1968); however, 
VPA and LEV were each used in almost 30% of episodes. This likely reflects clinician’s 
preferences to these compounds in situations where local or cardiac toxicity of PHT (Craig, 2005), 
or the risk of pharmacokinetic interactions with PHT and VPA, might be at play (Knake et al., 
2008).  
While treatment success rates after VPA were higher as compared to PHT and LEV in the 
univariate analysis, only the difference between VPA and LEV persisted after adjustment for 
etiology and SE severity (including age), two major predictors of SE outcome (Towne et al., 1994; 
Logroscino et al, 1997). Interestingly, the success rate among the 11 patients treated with other 
compounds was similar to that of VPA. It is unlikely that the observed differences resulted from 
systematic discrepancies in the loading or maintenance dosage of the second-line compounds. 
Actually, VPA was rather low-dosed in our hospital as compared to other series (Misra et al., 2006) 
and the most recent European guidelines (Meierkord 2010), whereas PHT was given as 
recommended by the European guidelines (Meierkord 2010); LEV was administered as previously 
reported in other centers (Knake et al. 2008; Berning et al., 2009) and the European guidelines 
(Meierkord 2010), where loading doses of at least 1000 mg and maintenance doses of about 2000 
mg are described. Furthermore, escalating LEV dosage beyond 3000 mg/day has not been shown to 
provide any additional benefit (Rossetti et al., 2006a). The fact that LEV was given orally in few 
subjects before its intravenous availability (June 2007) may theoretically have slowed its action; 
however, this occurred in only two patients, and they responded to the treatment; in fact, previous 
reports describe a definite effect after oral administration in SE (Rossetti et al., 2006a). 
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STESS and deadly etiology were robust predictors for outcome at discharge, independently of the 
type of second-line treatment. This reflects convergent information from several studies (Rossetti et 
al., 2006b; Towne et al., 1994; Logroscino et al., 1997), and suggests that various factors contribute 
to SE prognosis more than the specific antiepileptic therapy. In fact, differences in immediate SE 
control following the second-line drug might be “compensated” by the subsequent agent, suggesting 
that if the SE episode is per se treatable, it will respond to another drug. Again, it is tempting to 
assume that the biological background represents the major prognostic determinant (Rossetti et al., 
2006b; Towne et al., 1994). 
Our study has some limitations. Although we used a prospective database, data analysis was 
performed retrospectively for the purpose of this evaluation, and the treatment allocation was not 
randomized; therefore, we cannot exclude confounding factors. However, multivariable analyses 
were used to control for the most important known outcome predictors, including the STESS and 
the etiology; moreover, there was no significant difference in treatment delay between VPA and 
LEV. Less important predictors could not be assessed. These include adequacy of initial treatment 
with BZDs, duration of SE and timing of administration of second-line drugs. We did not 
specifically assess missed patients from the registry, but since in our hospital all subjects with a first 
seizure or SE suspicion have a neurological consultation and an EEG, it is relatively unlikely that 
problems with case ascertainment had major influence on the results of this study. In our database, a 
second-line treatment was given more frequently (198/279 episodes = 70%) as compared to the 
first-line failure rates in published trials (35% for lorezapam (Lowenstein et al., 1998), 40% for 
lorazepam and 57% for diazepam (Alldredge et al., 2001), 22% for lorazepam and 42% for 
diazepam (Leppik et al., 1983). We believe that several patients received a second-line agent shortly 
after benzodiazepines to prevent seizure recurrence (as it is commonly performed in clinical 
practice), leading to an overestimation of the efficacy of the three treatments. This reflects broadly 
used common practice (personal communications with several European and American SE 
specialists), and differs from the semi-artificial trial settings. However, it is unlikely that a specific 
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second-line agent was administered in case of “almost controlled” SE, generating a systematic bias. 
Furthermore, two senior epileptologists oversaw the vast majority of the treatment strategies, 
rendering unlikely a prescription bias by different physicians. The fact that in our series both PHT 
and VPA appeared less efficacious than previously reported (Agarwal et al., 2007) probably reflects 
a different etiological and demographical profile (India vs. Switzerland).  Finally, unfortunately our 
database does not allow extrapolating any estimation of specific side effects related to the analyzed 
treatments, nor to retrieve specific drug dosages. 
 
In conclusion, this study, which to the best of our knowledge represents the first comparison 
between PHT, VPA and LEV in SE, suggests some caution in the use of LEV in this setting, 
pending a well-designed comparative trial. Despite several putative difficulties in patients’ 
recruitment and organization, this approach appears clearly necessary to clarify this situation. 
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Table 1: Status Epilepticus Severity Score (STESS), a favorable score is 0–2. Adapted from 
Rossetti et al., 2008.  
 Features STESS 
   
Consciousness Alert or somnolent/confused 0 
 Stuporous or comatose 1 
   
Worst seizure type 
Simple-partial, complex-partial, absence, 
myoclonic* 0 
 Generalized-convulsive 1 
 Nonconvulsive status epilepticus in coma 2 
   
Age < 65 years 0 
 ≥ 65 years 2 
   
History of previous seizures Yes 0 
 No or unknown 1 
   
Total  0-6 
* complicating idiopathic generalized epilepsy  
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Table 2: Comparison of the groups of second-line treatment and the SE epilepticus characteristics 
 VPA PHT LEV p (test) Total 
 N=59 (29.8%) N=70 (35.4%) N=58 (29.3%)  N=187  
Deadly etiology 15 (25.4%) 39 (55.7%) 34 (58.6%) <0.001 (χ2) 88 (47.1%) 
Acute etiology 27 (45.8%) 45 (64.3%) 39 (67.2%) 0.035 (χ2) 111 (59.4%) 
STESS ≥3 26 (44.1%) 49 (70.0%) 29 (50%) 0.007 (χ2) 104 (55.6%) 
Alert/Confus/Somnolent 28 (47.5%) 23 (32.9%) 29 (50%) 0.101 (χ2) 70 (37.4%) 
Stupor/Coma 31 (52.5%) 47 (67.1%) 29 (50%) 0.101 (χ2) 107 (57.2%) 
GCSE + NCSEC 22 (37.3%) 41 (58.6%) 17 (29.3%) 0.002 (χ2) 80 (42.8%) 
No previous seizure 24 (40.7%) 48 (68.6%) 30 (51.7%) 0.006 (χ2) 102 (54.5%) 
Age: mean (SD) 64 (18.9) 57.8 (18.1) 66.1 (14.9) 0.02  (ANOVA) 62.4 (17.7) 
      
Failure of 2nd line 
treatment 15 (25.42%) 29 (41.42%) 28 (48.27%) 0.032 (χ2) 72 (38.5%) 
New morbidity or death at 
discharge 25 (42.37%) 45 (64.28%) 39 (67.24%) 0.011  (χ2) 109 (28.3%) 
Mortality/patients 4/48 (8.4%) 17/64 (26.6%) 9/47 (19.1%) 0.045 (Fisher) 30/159 (18.7%) 
 
GCSE= generalized convulsive status epilepticus, NCSE= nonconvulsive status epilepicus in coma, STESS= Status 
Epilepticus Severity Score, VPA= valproate, PHT= phenytoin, LEV= levetiracetam 
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Table 3: Deadly etiology, Status Epilepticus Severity Score (STESS) ≥3, PHT and LEV compared 
with VPA with logistic regression for the different outcomes: failure of 2nd line treatment, new 
morbidity or death and mortality 
 OR 95% CI p  
Failure of 2nd line 
treatment    
deadly etiology 0.997 0.53 - 1.89 0.995 
STESS ≥ 3 1.51 0.8 - 2.85 0.201 
Treatment (ref VPA)    
PHT as 2nd line 1.88 0.85 - 4.14 0.119 
LEV as 2nd line 2.69 1.19 - 6.08 0.017 
    
New morbidity or death at 
discharge     
deadly etiology 3.92 1.97 - 7.88 <0.001 
STESS ≥3 3.83 1.95 - 7.52 <0.001 
Treatment (ref VPA)       
PHT as 2nd line 1.35 0.6 - 3.02 0.463 
LEV as 2nd line 1.98 0.86 - 4.57 0.109 
    
Mortality    
deadly etiology 3.69 1.47 - 9.3 0.005 
STESS ≥3 3.56 1.32 - 9.61 0.012 
Treatment (ref VPA)    
PHT as 2nd line 1.34 0.43 - 4.12 0.607 
LEV as 2nd line 1.08 0.33 - 3.52 0.894 
STESS= Status Epilepticus Severity Score, VPA= valproate, PHT= phenytoin, LEV= levetiracetam 
 
